We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Latest Industry Insights
The Golden Age of Computer Assisted Structure Elucidation (CASE)
Industry Insight

The Golden Age of Computer Assisted Structure Elucidation (CASE)

Dimitris Argyropoulos explores the history of CASE and some of the ways it can be used to help scientists.
Simulator Technology Can Predict Optimal Vaccine Dosing
Industry Insight

Simulator Technology Can Predict Optimal Vaccine Dosing

Certara is developing biosimulation and tech-enabled approaches to help scientists answer key questions at various stages of the development pipeline, serving to inform and accelerate the path to regulatory approval. One such approach, the company’s Vaccine Simulator™, can be leveraged across different therapeutic areas to determine optimal vaccine dosing and dosing regimens for different patient cohorts.
Making Bioassay Data Easier To Retrieve and Share
Industry Insight

Making Bioassay Data Easier To Retrieve and Share

Technology Networks had the pleasure of speaking with Dr. Vladimir Makarov, project manager of the Pistoia Alliance Artificial Intelligence and Machine Learning Centre of Excellence, to learn more about the DataFAIRy project, its aims and importance.
Humanized Mice: Generation, Advantages and Applications
Industry Insight

Humanized Mice: Generation, Advantages and Applications

Technology Networks recently spoke with Dr. Marvin Ouyang, Cyagen’s executive vice president and chief scientific officer, to learn more about humanized mice and the applications they can benefit. In this interview Dr. Ouyang also explains how humanized mice can be generated and highlights some of Cyagen’s capabilities in this area.
Addyi – Analysis of the Potential Safety Signal
Industry Insight

Addyi – Analysis of the Potential Safety Signal

It was reported that the Food and Drug Administration (FDA) is looking into an adverse event spike for Sprout’s product Addyi. While the increase seems large, FDA will most likely not confirm this as a valid signal of new information about the benefit–risk profile of Addyi, based on our analysis of the underlying data.
Addressing the Challenges of Small Molecule Analysis
Industry Insight

Addressing the Challenges of Small Molecule Analysis

Despite small molecule research spanning many fields, the characterization and identification protocols are often not as good as they should be. We spoke to Andreas Huhmer from Thermo Fisher Scientific to learn how the company's latest mass spectrometer helps address these issues.
Connecting Biobanks With Biotech and Pharma Successfully
Industry Insight

Connecting Biobanks With Biotech and Pharma Successfully

Technology Networks recently had the pleasure of speaking with Robert Hewitt, founder and manager of Biosample Hub, a unique platform designed to connect biotech and pharmaceutical companies with biobanks. Biosample Hub aims to help scientists obtain the samples they need to support the testing and development of novel therapeutics, diagnostics and vaccines, while establishing and maintaining biospecimen provenance information.
Overcoming the Challenges of Lentiviral Vector Production
Industry Insight

Overcoming the Challenges of Lentiviral Vector Production

In this interview, Dr. Koh Meng Yong discusses the advantages of using lentiviral vectors and some of the applications they are enabling.
Tailoring LC Solutions for Growing Biopharma Demand
Industry Insight

Tailoring LC Solutions for Growing Biopharma Demand

Biopharmaceutical development is currently one of the fastest growing areas in the life sciences. With this comes an increasing need for analytical solutions able to cope with the challenges offered by biopharma samples. We spoke to Dr. Tom van de Goor from Agilent about how they are addressing these issues.
Drug Safety Testing – From Animals to "Clinical Studies on a Chip"
Industry Insight

Drug Safety Testing – From Animals to "Clinical Studies on a Chip"

There is increasing interest in finding and applying prediction models that are more physiologically relevant to humans, in particular those which can be used for the safety assessment of new drug candidates in more vulnerable patients. Rather than starting from a healthy animal or using animal models of disease, the use of patient tissues represents a major step forward.
Advertisement